Skip to main content

Advertisement

SpringerLink
Log in

JAK Inhibitors: What Is New?

  • Rheumatoid Arthritis (L Moreland, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

Three Janus kinase (JAK) inhibitors are approved for rheumatoid arthritis (RA) with a fourth awaiting approval. Multiple clinical trial results with these molecules have recently been reported. These were the first small molecule oral targeted synthetic DMARDs (tsDMARDs) to be approved for RA.

Recent Findings

Preclinical studies have suggested differential affinity for JAK isoform inhibition but it is not presently clear that there is any difference in efficacy in the clinic with these therapies. Preliminary data has suggested that filgotinib may have a modestly different safety profile but lacking direct comparisons, this will be difficult to confirm. Long-term safety studies have suggested similar safety signals to biologics although a possible signal for VTE/PE risk has been noted with tofacitinib and baricitinib.

Summary

Having an oral small molecule such as the JAK inhibitors with similar or better efficacy than biologics has been a major advance in RA treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377(6544):65–8. https://doi.org/10.1038/377065a0.

    Article  CAS  PubMed  Google Scholar 

  2. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–21. https://doi.org/10.1126/science.8197455.

    Article  CAS  PubMed  Google Scholar 

  3. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322. https://doi.org/10.1146/annurev.immunol.16.1.293.

    Article  CAS  PubMed  Google Scholar 

  4. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–87. https://doi.org/10.1111/j.1600-065X.2008.00754.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O’Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev. 2005;203:127–42. https://doi.org/10.1111/j.0105-2896.2005.00220.x.

    Article  CAS  PubMed  Google Scholar 

  6. Tokumasa N, Suto A, Kagami S, Furuta S, Hirose K, Watanabe N, et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood. 2007;110(2):553–60. https://doi.org/10.1182/blood-2006-11-059246.

    Article  CAS  PubMed  Google Scholar 

  7. Kahn C, Cohen S, Bradley J, et al: Tofacitinib for rheumatoid arthritis. Tofacitinib Arthritis Advisory Committee Meeting. May 9, 2012, Silver Spring, MD.

  8. Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM, et al. The specificity of JAK3 kinase inhibitors [published correction appears in Blood. 2009 Oct 1;114(14):3132. Dosage error in article text; Whipple, David A [added]]. Blood. 2008;111(4):2155–7. https://doi.org/10.1182/blood-2007-09-115030.

    Article  CAS  PubMed  Google Scholar 

  9. Conklyn M, Andresen C, Changelian P, Kudlacz E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol. 2004;76(6):1248–55. https://doi.org/10.1189/jlb.0504282.

    Article  CAS  PubMed  Google Scholar 

  10. Genovese M, Kawabata T, Soma K, et al: Reversibility of pharmacodynamics effects after short- and long-term treatment with tofacitinib in patients with rheumatoid arthritis. 2013. ACR meeting. Abstract 444.

  11. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–43. https://doi.org/10.4049/jimmunol.1003668.

    Article  CAS  PubMed  Google Scholar 

  12. Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM, et al. The specificity of JAK3 kinase inhibitors [published correction appears in Blood. 2009 Oct 1;114(14):3132. Dosage error in article text; Whipple, David A [added]]. Blood. 2008;111(4):2155–7. https://doi.org/10.1182/blood-2007-09-115030.

    Article  CAS  PubMed  Google Scholar 

  13. Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. https://doi.org/10.1186/s41927-018-0031-x.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Namour F, Diderichsen PM, Cox E, Vayssière B, van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–74. https://doi.org/10.1007/s40262-015-0240-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–38. https://doi.org/10.1021/jm401490p.

    Article  CAS  PubMed  Google Scholar 

  16. Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537. Published 2019 Nov 15. https://doi.org/10.1002/prp2.537.

    Article  PubMed  PubMed Central  Google Scholar 

  17. • Mc Innes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. https://doi.org/10.1186/s13075-019-1964-1 Published 2019 Aug 2. This study casts doubt on the selectivity of the approved JAK inhibitors with the doses used in the clinic.

    Article  Google Scholar 

  18. Lamba M, Wang R, Fletcher T et al. Evaluation of a single- dose and steady state pharmacokinetics, pharmacodynamics, bioavailibity and tolerability of the modified release formulation of tofacitinib versus the immediate release formulation of tofacitinib in healthy volunteers. EULAR meeting. Abstract THU0188.

  19. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–52. https://doi.org/10.1056/NEJMoa1507247.

    Article  CAS  PubMed  Google Scholar 

  20. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheum. 2017;69(3):506–17. https://doi.org/10.1002/art.39953.

    Article  CAS  Google Scholar 

  21. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [published correction appears in Ann Rheum Dis. 2017 Sep;76(9):1634]. Ann Rheum Dis. 2017;76(1):88–95. https://doi.org/10.1136/annrheumdis-2016-210094.

    Article  CAS  PubMed  Google Scholar 

  22. Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694–700. https://doi.org/10.1136/annrheumdis-2016-209821.

    Article  PubMed  Google Scholar 

  23. Namour F, Diderichsen PM, Cox E, Vayssière B, van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–74. https://doi.org/10.1007/s40262-015-0240-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Galien R, Brys R, Van der Aa A et al. Absence of effects of filgotinib on erythrocytes, CD8+ and NK cells in rheumatoid arthritis patients brings further evidence for the JAK1 selectivity of filgotinib. 2015. ACR meeting Abstract 2781.

  25. Fleischmann R, Pangan A, Mysler E et al. A phase 3, randomized double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. 2018. ACR meeting abstract 890.

  26. Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–800. https://doi.org/10.1002/art.41032.

    Article  CAS  PubMed  Google Scholar 

  27. Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78(10):1305–19. https://doi.org/10.1136/annrheumdis-2019-215164.

    Article  CAS  PubMed  Google Scholar 

  28. Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78(10):1320–32. https://doi.org/10.1136/annrheumdis-2019-215163.

    Article  CAS  PubMed  Google Scholar 

  29. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507. https://doi.org/10.1056/NEJMoa1109071.

    Article  CAS  PubMed  Google Scholar 

  30. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–61. https://doi.org/10.7326/0003-4819-159-4-201308200-00006.

    Article  PubMed  Google Scholar 

  31. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, ORAL Standard Investigators Tofacitinib or adalimumab versus placebo in rheumatoid arthritis [published correction appears in N Engl J Med. 2013 Jul 18;369(3):293]. N Engl J Med 2012;367(6):508–519. https://doi.org/10.1056/NEJMoa1112072.

  32. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–60. https://doi.org/10.1016/S0140-6736(12)61424-X.

    Article  CAS  PubMed  Google Scholar 

  33. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–70. https://doi.org/10.1002/art.37816.

    Article  CAS  PubMed  Google Scholar 

  34. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–86. https://doi.org/10.1056/NEJMoa1310476.

    Article  CAS  PubMed  Google Scholar 

  35. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457–68. https://doi.org/10.1016/S0140-6736(17)31618-5.

    Article  CAS  PubMed  Google Scholar 

  36. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–52. https://doi.org/10.1056/NEJMoa1507247.

    Article  CAS  PubMed  Google Scholar 

  37. Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheum. 2017;69(3):506–17. https://doi.org/10.1002/art.39953.

    Article  CAS  Google Scholar 

  38. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [published correction appears in Ann Rheum Dis. 2017 Sep;76(9):1634]. Ann Rheum Dis. 2017;76(1):88–95. https://doi.org/10.1136/annrheumdis-2016-210094.

    Article  CAS  PubMed  Google Scholar 

  39. Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694–700. https://doi.org/10.1136/annrheumdis-2016-209821.

    Article  PubMed  Google Scholar 

  40. Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–24. https://doi.org/10.1016/S0140-6736(18)31116-4.

    Article  CAS  PubMed  Google Scholar 

  41. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–12. https://doi.org/10.1016/S0140-6736(18)31115-2.

    Article  CAS  PubMed  Google Scholar 

  42. Smolen J, Pangan AL, Emery P, et al. Upadacitinib as monotherapy: a phase 3 randomized controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. Lancet. 2019 Jun 8;393(10188):2303–11. https://doi.org/10.1016/S0140-6736(19)30419-2.

    Article  PubMed  Google Scholar 

  43. • Fleischmann R, Pangan A, Mysler E, et al. A Phase 3, Randomized double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Ann Rheum Dis. 2019;0:1–9. https://doi.org/10.1136/annrheumdis-2019-215764Clinical trial demonstrating superiority of upadacitinib to adalimumab in clinical response in methotrexate incomplete responders.

    Article  CAS  Google Scholar 

  44. Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheum. 2017;69(5):932–42. https://doi.org/10.1002/art.40054.

    Article  CAS  Google Scholar 

  45. Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheum. 2017;69(4):709–19. https://doi.org/10.1002/art.39955.

    Article  CAS  Google Scholar 

  46. • Genovese M, Kalunian K, Walker D, et al. Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic Dmard. JAMA. 2019;322(4):315–25. https://doi.org/10.1001/jama.2019.9055First publication of clinical trial results with filgotinib in biologic refractory population.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–800. https://doi.org/10.1002/art.41032.

    Article  CAS  PubMed  Google Scholar 

  48. Combe B, Kivitz A, Tanaka Y, van der Heijde D, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy J, Mozaffarian N, Landewé R, Bae S, Keystone E, Nash P. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Abstract: 2019 ACR meeting.

  49. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–62. https://doi.org/10.1056/NEJMoa1608345.

    Article  CAS  PubMed  Google Scholar 

  50. Combe B, Kivitz A, Tanaka Y et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis naïve to methotrexate therapy: finch 1 primary outcome results. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A77.

  51. Westhovens R, Rigby W, van der Heijde D et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis naïve to methotrexate therapy: finch 3 primary outcome results. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A259.

  52. Strand V, van Vollenhoven RF, Lee EB, Fleischmann R, Zwillich SH, Gruben D, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford). 2016;55(6):1031–41. https://doi.org/10.1093/rheumatology/kev442.

    Article  CAS  Google Scholar 

  53. Strand V, Mysler E, Moots RJ, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5(2):e001040. Published 2019 Oct 1. https://doi.org/10.1136/rmdopen-2019-001040.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694–700. https://doi.org/10.1136/annrheumdis-2016-209821.

    Article  PubMed  Google Scholar 

  55. Schiff M, Takeuchi T, Fleischmann R, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther. 2017;19(1):208. Published 2017 Sep 18. https://doi.org/10.1186/s13075-017-1410-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Strand V, Pope J, Tundia N, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21(1):272. Published 2019 Dec 9. https://doi.org/10.1186/s13075-019-2037-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Strand V, Schiff M, Tundia N, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263. Published 2019 Dec 2. https://doi.org/10.1186/s13075-019-2059-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Genovese M, Westhovens R, Meuleners L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018;20(1):57. Published 2018 Mar 23. https://doi.org/10.1186/s13075-018-1541-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. • Cohen S, Tanaka Y, Mariette X et al: Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development program. 2018. ACR meeting. Abstract 963. Review of adverse event profile from the long-term extension protocol in RA patients on tofacitinib with over 22,000 patient years exposure.

  60. Kavanaugh A,Genovese M, Winthrop et al. Rheumatoid arthritis treatment with filgotinib: week 132 safety data from a phase 2b open-label extension study.2018. ACR meeting. Abstract 255.1.

  61. Genovese M,Smolen J,Takeuchi T et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 6 years: an updated integrated safety analysis. 2018. ACR meeting. Abstract 962.

  62. Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66(11):2924–37. https://doi.org/10.1002/art.38779.

    Article  CAS  Google Scholar 

  63. Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment [published correction appears in J Rheumatol. 2019 Dec;46(12):1648-1649]. J Rheumatol. 2019;46(1):7–18. https://doi.org/10.3899/jrheum.171361.

    Article  CAS  PubMed  Google Scholar 

  64. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66(10):2675–84. https://doi.org/10.1002/art.38745.

    Article  CAS  Google Scholar 

  65. Winthrop K, Genovese M, Combe B, Tanaka Y, Kivitz A, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy J, Keystone E, Westhovens R, Rigby W, Burmester G. Pooled safety analyses from phase 3 studies of filgotinib in patients with rheumatoid arthritis. 2019. ACR meeting. Abstract 1329.

  66. Curtis JR, Xie F, Chen L, Spettell C, McMahan RM, Fernandes J, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum. 2011;63(2):346–51. https://doi.org/10.1002/art.30107.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774–80. https://doi.org/10.1136/annrheumdis-2013-203380.

    Article  PubMed  Google Scholar 

  68. Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Aviña-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis. 2013;72(7):1182–7. https://doi.org/10.1136/annrheumdis-2012-201669.

    Article  PubMed  Google Scholar 

  69. Weinblatt M, Taylor P, Burmester G et al. Cardiovascular safety-update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials. 2018. ACR meeting.abstract 2815.

  70. FDA Baricitinib Arthritis Advisory Board 2018.

  71. Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048–54. https://doi.org/10.1136/annrheumdis-2018-214846.

    Article  CAS  PubMed  Google Scholar 

  72. ClinicalTrials.govidentifier NCT01932372.

  73. • EMA, 2019. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. [online] This press release describes the data on which the EMA based its recommendation to limit the use of tofacitinib in certain settings. Available at: <https://www.ema.europa.eu/en/news/ema-confirms-xeljanz-be-used-caution-patients-high-risk-blood-clots> Accesd 2020 Nov.

  74. Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46(1):71–80. https://doi.org/10.1016/j.semarthrit.2016.03.004.

    Article  CAS  PubMed  Google Scholar 

  75. McInnes IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73(1):124–31. https://doi.org/10.1136/annrheumdis-2012-202442.

    Article  CAS  PubMed  Google Scholar 

  76. Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014;16(4): R158. Published 2014 Jul 25. https://doi.org/10.1186/ar4673.

  77. Kremer J, Cappelli L et al.: Real-world data from a post-approval safety surveillance study of tofacitinib vs biologic dmards and conventional synthetic dmards: five-year results from a US-based rheumatoid arthritis registry. 2018. ACR Meeting. Abstract 1542.

  78. Harnett J, Curtis JR, Gerber R, Gruben D, Koenig A. Initial experience with tofacitinib in clinical practice: treatment patterns and costs of tofacitinib administered as monotherapy or in combination with conventional synthetic DMARDs in 2 US health care claims databases [published correction appears in Clin Ther. 2016 Nov;38(11):2506-2507]. Clin Ther. 2016;38(6):1451–63. https://doi.org/10.1016/j.clinthera.2016.03.038.

    Article  CAS  PubMed  Google Scholar 

  79. Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm. 2016;22(12):1457–71. https://doi.org/10.18553/jmcp.2016.22.12.1457.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Texas Health Dallas Presbyterian Hospital, Dallas, TX, USA

    Virginia Reddy

  2. UT Southwestern Medical School, Dallas, TX, USA

    Stanley Cohen

  3. Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, TX, 75231, USA

    Stanley Cohen

  4. Texas Health Dallas Presbyterian Hospital, Dallas, TX, USA

    Stanley Cohen

Authors
  1. Virginia Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stanley Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanley Cohen.

Ethics declarations

Conflict of Interest

Dr. Cohen reports that he has been a consultant and investigator for AbbVie, Gilead, Lilly, and Pfizer.

Dr. Reddy has no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Topical Collection on Rheumatoid Arthritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reddy, V., Cohen, S. JAK Inhibitors: What Is New?. Curr Rheumatol Rep 22, 50 (2020). https://doi.org/10.1007/s11926-020-00931-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-020-00931-6

Keywords

Search

Navigation